Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT06378827 |
| Other study ID # |
418-1/2 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
Phase 2/Phase 3
|
| First received |
|
| Last updated |
|
| Start date |
April 3, 2024 |
| Est. completion date |
October 2024 |
Study information
| Verified date |
April 2024 |
| Source |
University of Novi Sad |
| Contact |
Ranko Zdravkovic |
| Phone |
+381654674620 |
| Email |
ranko.zdravkovic[@]mf.uns.ac.rs |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
This is a prospective randomized clinical trial designed to determine the effect of
intraoperative dexmedetomidine administration on renal function after coronary artery bypass
graft surgery.
Description:
This study will include patients admitted to the Clinic for Cardiovascular Surgery of the
Institute of Cardiovascular Diseases of Vojvodina, planned for elective coronary artery
bypass graft surgery (CABG). Basic demographic and anthropometric data (gender, age, height,
weight, and body mass index) and data on comorbidities, therapy, and allergies will be
recorded. The day before surgery, all patients will undergo transthoracic echocardiography,
on the basis of which the ejection fraction of the left ventricle will be determined and
recorded. After the entire examination, the New York Heart Association (NYHA) class, American
Society of Anaesthesiologists physical status (ASA score), and Estimate risk of in-hospital
death after cardiac surgery score (EuroSCORE II) will be determined. The method and purpose
of the research will be explained to all patients, after which informed consent for
participation in the research will be obtained.
The patients will be divided into two groups (experimental and control) using the
randomization method. All patients will have blood drawn for laboratory and biochemical
analyses the morning before surgery: urea, creatinine, cystatin C, IL-6, hemoglobin,
leukocytes, platelets, glycemia, aspartate aminotransferase (AST), alanine transaminase
(ALT), lactate dehydrogenase (LDH), direct and total bilirubin, fibrinogen, CRP, CK-MB, hS
troponin I, electrolytes (Na+ and K+), and lactates. With the help of the Cockcroft-Gault
formula, the estimated glomerular filtration rate (eGFR) and creatinine clearance (CCr) will
be determined. The values of all these analyses will be defined as basal values.
The anesthetic and surgical protocol, as well as the postoperative treatment, will be
standardized. Half an hour before arriving in the operating room, patients will receive about
0.05 mg/kg of midazolam per os as premedication. Upon arrival in the operating room,
electrodes for continuous monitoring of the electrocardiogram (ECG), electrodes for assessing
the depth of anesthesia, and pulse oximetry for monitoring pulse saturation (SpO2) will be
attached to all patients. Anesthetist nurses will place a peripheral venous cannula, usually
in one of the veins of the right arm, through which infusion solutions will be applied in the
perioperative period and if necessary, transfusions of autologous blood, resuspended
erythrocytes, platelets, and fresh frozen plasma. The anesthesiologist will place the
arterial cannula, mostly in the left radial artery, for continuous monitoring of arterial
blood pressure values. After adequate preoxygenation (8 l/min, 3 min) via a ventilation mask,
the intravenous anesthesia will be administered with a combination of the benzodiazepine
midazolam (about 0.05 mg/kg), the opioid analgesic sufentanil (about 0.15 µg/kg), intravenous
anesthetic propofol (about 1 mg/kg), and the neuromuscular relaxant rocuronium bromide (about
0.8 mg/kg). After endotracheal intubation, patients will be on mechanical lung ventilation
(MLV) - volume-controlled ventilation mode with a tidal volume of 6-8 ml/kg of ideal body
weight, a respiratory rate of 12/min, FiO2 of 0.5, a positive end-expiratory pressure (PEEP)
of 5 cmH2O, and an inspiratory ratio to expirium - I:E 1:2. The flow of fresh gases at the
MLV in all patients will be 3 l/min. Correction of MLV parameters will be done based on
partial pressures of oxygen (PaO2) and carbon dioxide (PaCO2) in arterial blood, with the aim
of maintaining PaO2 >100 mmHg and PaCO2 35-45 mmHg. A three-lumen central venous catheter
(CVC) will be placed mainly in the right interior jugular vein. All patients will be placed
with a urinary catheter to monitor hourly diuresis as well as a nasopharyngeal probe to
monitor nasopharyngeal temperature.
Dexmedetomidine solution will be prepared by diluting one ampoule of dexmedetomidine
(200µg/2ml) with 48 ml of saline solution to obtain a dexmedetomidine solution of 4µg/ml.
Patients from the experimental group will receive a continuous infusion of dexmedetomidine at
a dose of 0.5 µg/kg/h, until the end of the operation. Patients in the control group will
receive the same volume of saline solution.
Anesthesia will be maintained with the inhaled anesthetic sevoflurane, with target depth of
anesthesia values between 40 and 60, as measured by entropy. A continuous intravenous
infusion of sufentanil (0.5-1 µg/kg/h) will be used for intraoperative analgesia.
Neuromuscular relaxation will be maintained by intermittent bolus doses of rocuronium bromide
(on average, about 0.4 mg/kg/h). All patients will receive an intravenous antibiotic
(Ceftriaxone 1g) half an hour before the surgical incision, and in cases of allergy to
cephalosporins, Vancomycin 500 mg. All patients are prescribed tranexamic acid according to
the protocol.
All operations will be performed through a medial sternotomy approach. To achieve total
heparinization, heparin will be prescribed at a dose of 300-400 IU/kg. After 5 minutes from
the administration of heparin, arterial blood will be drawn to determine the activated
coagulation time, i.e, ACT. After reaching the value of ACT >480 s, cardiopulmonary bypass
(CPB) will be started. During that period, the inhalation anesthetic will be turned off, and
anesthesia will be maintained with a continuous infusion of propofol. During the application
of the CBP pump, MLV will be performed with a tidal volume of 2-3 ml/kg of ideal body weight,
a respiratory rate of 10/min, an FiO2 of 0.5, and a PEEP of 5 cmH2O. Membrane oxygenators
will be used for CPB, which will be "primed" with 1500 ml of Hartmann's solution and 2500 IU
of heparin. The flow rate of the CPB non-pulsating pump will be 2-2.4 l/min/m2. The value of
mean arterial pressure during CPB will be maintained between 50 and 80 mmHg. Hemoglobin
values will be maintained above 8 g/dl, and hematocrit values will be above 0.22. In cases of
lower values, resuspended erythrocytes will be prescribed. Crystalloid cardioplegic solution
or blood cardioplegia will be used to stop and protect the myocardium. All operations will be
performed under conditions of mild hypothermia (33-34°C). It will be recorded whether the
heart, after removing the aortic clamp, worked spontaneously, whether it was defibrillated
with an internal defibrillator, or whether a temporary pacemaker was applied. To reverse the
effect of heparin, after the completion of CPB and removal of the cannula for CPB, protamine
sulfate will be prescribed at a dose of 1 mg per 100 IU of heparin.
During the operation, the anesthesiologist will record the values of systolic and diastolic
arterial blood pressure and heart rate every 5 minutes, the values of central venous
pressure, SpO2, and depth of anesthesia every 15 minutes, as well as hourly diuresis in the
anesthesia chart. The presence of significant arterial hypotension (mean arterial pressure <
65 mmHg or < 50 mmHg during CPB) lasting at least 5 min will be recorded, and whether it
lasted 5-15, 15-30 or longer than 30 min will be recorded. The length of application of the
aortic clamp, the length of application of the CPB pump, and the length of the operation will
be recorded. The total doses of propofol (mg), sufentanil (µg), and the volume of sevoflurane
(ml) administered during the operation will be recorded, as well as the total volume of
Hartmann's solution, cardioplegia solution, and eventual transfusion of autologous blood,
resuspended erythrocytes, platelets, and fresh frozen plasma. It will be recorded whether the
patient was prescribed antihypertensives, sympathomimetics, parasympatholytics, inotropics,
and vasopressor support, in what doses, and for what period of time if a continuous infusion
was used.
After surgery, the patients will be sedated with a continuous infusion of propofol (about 2
mg/kg/h) and on MLV and will be transferred to the ICU, where, after meeting the criteria
necessary for separation from MLV, they will be extubated. Continuous monitoring (ECG,
invasive arterial pressure, central venous pressure, SpO2, hourly diuresis, body temperature,
arterial blood gas analysis) continues during the stay of patients in the intensive care unit
(ICU) and in the semi-intensive care unit. On the first three days (the day of surgery and
the first two postoperative days), the presence of mean arterial pressure < 65 mmHg will be
recorded, and it will be noted whether it lasted less than 1 hour, 1-3 hours, 3-6 hours, or
more than 6 hours. The intake of crystalloid solutions, resuspended erythrocytes, fresh
frozen plasma, and platelets will be monitored and recorded. Daily diuresis, daily blood
loss, the amount of prescribed diuretics during 24 hours, as well as the use of inotropes,
will be recorded. During the first three days, the presence of oliguria (<0.5 ml/kg) will be
recorded and noted, whether it lasted 6-12 hours or longer than 12 hours, the presence of
severe oliguria (<0.3 ml/kg) lasting longer than 24 hours, or the presence of anuria lasting
longer than 12 hours.
On the first postoperative day, all laboratory and biochemical analyses that were performed
preoperatively will be repeated (urea, creatinine, cystatin C, IL-6, hemoglobin, leukocytes,
platelets, glycemia, AST, ALT, LDH, direct to total bilirubin, fibrinogen, CRP, CK-MB, hS
troponin I, Na+, K+ and lactates). On the second postoperative day, serum cystatin C,
creatinine, Na+, K+ and lactate analyses will be repeated. Creatinine values will be
determined on the third and fifth postoperative day. Based on each new creatinine value, eGFR
and CCr will be determined.
For all patients, the length of postoperative MLV (in hours), the length of stay in the ICU
(in days), the length of hospitalization after surgery (in days), and possibly death will be
recorded.
The primary objective of the study will be to monitor and compare, between groups, indicators
of renal function (serum creatinine, cystatin C, diuresis, eGFR, and CCr). The changes of all
these values in relation to the basal values will be monitored, in order to determine when
the greatest changes in the values of the indicators of renal function occur. Of particular
importance will be the correlation between serum cystatin C and creatinine values. During the
first three days, daily diuresis, the volume of prescribed liquids, the administration and
doses of diuretics, and the values of Na+, K+, and lactate will be monitored and compared.
The frequency of the occurrence of acute kidney injury (AKI) will be monitored. The diagnosis
of AKI will be based on the criteria of the KDIGO guide.
The change of inflammatory markers (IL-6, CRP, leukocytes, fibrinogen) in relation to basal
values is also one of the primary goals of the research. Inflammatory markers will be checked
on the first postoperative day, when the inflammatory response is most pronounced. A
correlation will be made between IL-6 and other inflammatory markers that are in routine
clinical use (CRP, leukocytes, and fibrinogen) in order to determine which inflammatory
marker correlates best with IL-6. A correlation between IL-6 values and serum creatinine and
cystatin C values will also be performed, in order to determine whether impairment of renal
function is related to the intensity of the inflammatory response.
